FDA approves new uses for two drugs administered together for the treatment of BRAF-positive anaplastic thyroid cancer

By May 5, 2018 March 3rd, 2024 Past News Releases, Thyroid Cancer

The U.S. Food and Drug Administration approved Tafinlar (dabrafenib) and Mekinist (trametinib), administered together, for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has spread to other parts of the body (metastatic), and has a type of abnormal gene, BRAF V600E (BRAF V600E mutation-positive). Read the FDA’s press release for more information.